Browse Category

SGX:C76.SI News 26 August 2025

Creative Pebble Nova: The $280 Desktop Speakers Shaking Up PC Audio in 2025

Creative Pebble Nova: The $280 Desktop Speakers Shaking Up PC Audio in 2025

Key Facts Market Availability and Pricing Creative clearly intended the Pebble Nova to bridge the gap between cheap PC speakers and true bookshelf speakers, and this is reflected in its pricing and market position. With an MSRP of $279.99 in the U.S. techradar.com (and roughly £239.99 in the UK/AU$499.95 in Australia), the Nova costs several times more than any previous Pebble model. By contrast, the popular Pebble V3 launched at around $40–$50, and even the feature-rich Pebble Pro was about $60–$80. In fact, before the Nova, Creative’s Pebble X (released in 2023) was the priciest of the series at ~$89
26 August 2025

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop